Common clinical plans
Following your appointment in the menopause and PMS clinic, an individualised treatment plan will have been agreed in your clinical summary shared with your GP. Common clinical treatment plans with signposts to useful resources are available here.
On this page
- Investigations
- Resources
- Premature ovarian insufficiency (POI)
- Low libido and testosterone replacement
- Genitourinary symptoms of the menopause (GSM)
- Hormone implant clinic
- Progestogen regimens in combined HRT
Investigations
| Serum estradiol (E2), luteinising hormone (LH), follicle stimulating hormone (FSH) | Blood test for diagnosis and assess treatment |
| Anti-Müllerian hormone (AMH) | Blood test to assess fertility |
| Genetics testing (in POI) | To identify potential cause of POI
|
| DEXA bone density scan (BMD) | X-ray of spine and hip to assess risk of osteoporosis |
| Transvaginal ultrasound scan (TVUSS) | To assess the womb (uterus), womb lining (endometrium) and ovaries An antra follicle count (AFC) may be requested if assessing fertility The AFC is the number of small immature follicles seen within the ovary |
| Dietary calcium check | Online self-assessment Calcium supplements are not generally recommended if you have a calcium rich diet Excess calcium intake can lead to deposits around the heart and in breast tissue, potentially increasing long-term health risk |
Resources
- British Menopause Society (BMS)
- Menopause Matters
- Women's Health Concern (WHC)
- DAISY Network (POI)
- ESHRE POI guidelines
- HFEA UK fertility regulator
- Recommended book: Living Well Through the Menopause: An Evidence-Based Cognitive Behavioural Guide by Myra Hunter and Melanie Smith. Robinson, 2024. ISBN: 9781472148384. Available from bookshops and online booksellers
Premature ovarian insufficiency (POI)
POI is a diagnosis made in women under the age of 40. Due to the loss of estrogen, hormone replacement may be advised for symptom relief as well as long-term heart bone and brain heath. Hormone replacement may be either a combined hormonal contraception or with hormone replacement therapy (HRT). The decision is very personal and guided by your specialist.
If you have been diagnosed with POI you be interested in joining the POISE multicentre trial comparing the benefit of different hormone treatments.
Low libido and testosterone replacement
Starting and monitoring testosterone
- A blood test to measure your testosterone level is required before starting treatment.
- Your testosterone level will be monitored during treatment to ensure it remains within the female physiological range.
- Treatment is assessed mainly by whether your symptoms improve and whether you develop side-effects.
- If side-effects occur, reducing the dose or frequency may help.
- Treatment should usually be stopped if there has been no meaningful improvement after 3–6 months.
Testosterone preparations
- Testogel 40.5 mg/2.5 g sachet: approximately one-eighth of a sachet each day.
- Tostran 2% gel: one measured pump (10 mg), usually applied on alternate days.
- AndroFeme 1% cream: 0.5 mL (5 mg) applied once daily. This is formulated specifically for women but is not routinely available on the NHS and may require private or specialist prescribing.
Applying testosterone
Possible side-effects
- Increased facial or body hair
- Acne or oily skin
- Hair thinning
- Weight gain
- Voice deepening
Genitourinary symptoms of the menopause (GSM)
When to seek medical advice
Treatments for GSM
- Vaginal moisturisers can be used regularly to help improve dryness and discomfort. Examples include Hyalofemme, YES VM and Replens.
- Lubricants can be used during sex to reduce friction and discomfort. Examples include YES WB and Sylk.
- Oil-based products may damage latex condoms and other latex barrier contraception.
- Avoid perfumed soaps, washes and vaginal douches, as these can cause irritation. A soap-free emollient may be more comfortable for washing the vulval area.
Vaginal oestrogen
- Estradiol vaginal tablets or pessaries, including Gina, which is available from pharmacies without a prescription for eligible women.
- Estriol vaginal cream or gel.
- Other vaginal oestrogen preparations may be prescribed depending on individual needs and availability.
Other treatment options
- Prasterone (Intrarosa) may be considered for vaginal atrophy and pain during sex where appropriate.
- Ospemifene (Senshio) may be considered for moderate to severe vulval and vaginal symptoms where appropriate.
- Pelvic health physiotherapy may help with pain during sex, pelvic floor problems or associated bladder symptoms.
- Referral to a specialist vulval or dermatology clinic may be appropriate if persistent vulval symptoms do not improve or the diagnosis is uncertain.
Hormone implant clinic
Before booking your next hormone implant appointment
- Your serum oestradiol level is below 600 pmol/L, or below the individual threshold agreed in your clinical plan.
- Your menopause symptoms have returned.
- At least 6 months have passed since your last implant.
Wound infection and implant rejection
- Increasing or spreading redness, swelling or warmth around the wound
- Pain or tenderness that is getting worse
- Yellow or green discharge or pus from the wound
- The wound opening or not healing as expected
- Fever or feeling generally unwell
Implant shortages: Estrogen implants are unlicensed in the UK and imported from the United States. The manufacturer has stopped producing these implants, and previous estimates suggested that supplies for existing patients in England would last until April 2026. Future availability remains uncertain. If implants are no longer available, we will discuss suitable alternative treatment options with patients on an individual basis.
Progestogen options in combined HRT
Sequential progestogen regimens
- Micronised progesterone 200 mg: 200 mg taken orally at night for 12 consecutive nights each month.
- Micronised progesterone 200 mg vaginally: 200 mg inserted vaginally at night for 12 consecutive nights each month. Off-label route.
- Dydrogesterone 10 mg: 10 mg taken orally once daily for 12–14 consecutive days each month.
- Norethisterone 5 mg: 5 mg taken orally once daily for 10–12 consecutive days each month. Stand-alone use as part of HRT is off-label.
- Medroxyprogesterone acetate (Provera) 10 mg: 10 mg taken orally once daily for 10–12 consecutive days each month.
- 52 mg levonorgestrel intrauterine system: Provides continuous endometrial protection alongside oestrogen. Duration of use for endometrial protection should follow current product licensing and clinical guidance.
Continuous progestogen regimens
- Micronised progesterone 100 mg capsule: 100 mg taken orally every night.
- Micronised progesterone 100 mg capsule vaginally: 100 mg inserted vaginally every night. Off-label route.
- Lutigest 100 mg pessary: 100 mg inserted vaginally every night. Off-label for endometrial protection as part of HRT.
- Dydrogesterone 5 mg: 5 mg taken orally every day.
- Norethisterone 5 mg: 5 mg taken orally every day. Stand-alone use as part of HRT is off-label.
- Medroxyprogesterone acetate (Provera) 5 mg: 5 mg taken orally every day.
- 52 mg levonorgestrel intrauterine system: Provides continuous endometrial protection as part of HRT. Duration of use for endometrial protection should follow current product licensing and clinical guidance.